362 results about "Treatment medication" patented technology

The invention relates to an application of Danjie emodin in preparation of drugs for preventing or treating drug-induced liver injury. The liver injury is drug-induced liver injury induced by acetaminophen. According to the invention, the effective component Danleaf emodin in the traditional Chinese medicine rhubarb is used for preventing and treating drug-induced liver injury induced by acetamido, and the traditional Chinese medicine composition has the characteristics of safety, reliability and small toxic and side effects. Starting from the whole, multi-target intervention is performed on drug-induced liver injury induced by acetaminophen, the levels of glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and malondialdehyde in plasma are remarkably reduced, the obvious anti-inflammatory and liver cell apoptosis inhibiting effects are achieved, the good clinical application prospect is achieved, and a new way is provided for prevention and treatment of liver injury.

The invention aims to provide a preparation method and application of an inhalation drug-loading ultrasonic driving nano motor, and can effectively solve the problems of preparation of the inhalation drug-loading ultrasonic driving nano motor and application of the inhalation drug-loading ultrasonic driving nano motor in preparation of drugs for treating IPF. Comprising the following steps: firstly preparing PLGA-PFD nanoparticles, then preparing PDA-PLGA-PFD nanoparticles, and finally preparing BNN6 / PDA-PLGA-PFD, namely the asymmetric nano motor BPPP with the ultrasonic responsiveness. The product disclosed by the invention is scientific and advanced in preparation method, good in product performance, high in atomization administration and IPF lung pathological barrier penetrating capability, high in medicine utilization rate, good in curative effect, simple and convenient to operate, wide in application prospect and huge in economic and social benefits.

The invention discloses an application of core proteoglycan or a coding gene thereof as a target spot in preparation of psoriasis treatment drugs, and a series of experiments prove that DCN can effectively protect mouse psoriasis-like dermatitis induced by imiquimod, improve skin scale, erythema, thickening and epidermal abnormal differentiation, enhance the barrier function of skin, improve the curative effect of psoriasis, and improve the curative effect of psoriasis. A large amount of infiltration of inflammatory cells is reduced, and a certain anti-inflammatory effect is achieved. Experimental research shows that the DCN has an obvious drug effect on a psoriasis model, is safe and efficient, has no side effect, is simple in production process and has the potential of realizing medical transformation. And the potential application value of the DCN on other various skin inflammatory diseases can be expanded.

The invention provides a bending-adjustable balloon micro-catheter, and belongs to the technical field of balloon micro-catheters.The bending-adjustable balloon micro-catheter comprises a catheter body, a balloon, a bending mechanism and a feedback mechanism, the catheter body is of a slender tubular structure, and an inner cavity of the catheter body is used for conveying therapeutic drugs or embolism materials or other media; the balloon is located at the far end of the catheter body, is in an ellipsoidal shape and is used for blocking blood flow or expanding blood vessels. The multiple bending mechanisms are sequentially located at the middle section position of the catheter body and are composed of shape memory alloy wires, and the shape memory alloy wires are spirally wound around the outer wall of the catheter body, connected to the catheter body and used for adjusting the bending angle and direction of the catheter body; the feedback mechanisms are pressure sensor arrays, and the number of the feedback mechanisms is eight. The problems that an existing balloon micro-catheter is difficult to accurately reach a target position in a complex blood vessel or cavity, and the blood vessel is prone to being damaged can be solved.

The present invention provides a novel therapeutic drug for treating a Prom1-associated retinal disease. Specifically, the present invention provides an optimized Prom1 gene expression cassette, an rAAV viral vector, and a gene therapy drug. The drug of the present invention can specifically express the PROM1 protein in the retinal photoreceptor layer, and is suitable for the clinical treatment of a retinal disease associated with Prom1 gene mutation.

The invention relates to the field of biomedicine, particularly provides a copper-based nano-enzyme as well as a preparation method and application thereof, and aims to solve the problems that in the prior art, clinical treatment on primary sclerosing cholangitis (PSC) is difficult in diagnosis and lacks of effective treatment drugs. The copper-based nano-enzyme comprises a nano-enzyme carrier and a copper-based nano-enzyme, wherein the nano-enzyme carrier is a two-dimensional nanosheet formed by copper ions, gallic acid and ursodesoxycholic acid through coordinate bonds; the probe molecule is a cyanine dye molecule connected to the surface of the nano-enzyme carrier through a covalent bond; wherein the fluorescence intensity of the copper-based nano enzyme is enhanced after the action of the alkaline phosphatase. The three functions of alkaline phosphatase responsive diagnosis, nano-enzyme catalytic treatment and ursodesoxycholic acid hepatic targeting are innovatively and synergistically integrated into one nano platform, the treatment function can be executed while specific imaging diagnosis is performed on diseases, and a new strategy is provided for diagnosis and treatment of diseases such as PSC.

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

The invention discloses nano-particles with antibacterial and osteogenesis promoting effects as well as a preparation method and application of the nano-particles, and belongs to the technical field of antibacterial nano-materials. On one hand, the invention provides the nano-particles with antibacterial and osteogenesis promoting effects and the preparation method thereof, and on the other hand, the invention provides the application of the nano-particles. The nanoparticles obtained by the method disclosed by the invention have good stability under physiological conditions (PH = 7.4); polyphenol, metal ions and AMP (adenosine monophosphate) can be slowly released in an inflammatory (weakly acidic) environment, and the functions including but not limited to bacterium capturing, bacterium killing, inflammation and oxidation resisting, osteogenesis promoting and the like are realized; the nano-particles can be used for preparing a bone infection treatment drug, and the bone infection treatment drug has a broad-spectrum antibacterial effect and cannot cause antibiotic drug resistance; the treatment medicine can efficiently prevent and treat bone infection and improve bone repair efficiency.

The invention discloses application of GSK2606414 in preparation of a medicine for inhibiting duck tembusu virus infection, and belongs to the technical field of veterinary biological products. The research finds that the GSK2606414 can effectively inhibit the replication of the duck tembusu virus for the first time, provides a new therapeutic drug for the prevention and treatment of the duck tembusu virus, and is of great significance to the actual production of the poultry breeding industry.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a traditional Chinese medicine composition in preparation of anti-hepatoma medicines. The traditional Chinese medicine composition comprises red ginseng, ox horn tip, musk, borneol, safflower, bezoar, radix aconiti lateralis praeparata slice, venenum bufonis, pseudo-ginseng, benzoin and pearl. Experimental results show that the traditional Chinese medicine composition can induce apoptosis and necrosis of liver cancer cells and inhibit proliferation of the liver cancer cells; and liver cancer cells are retarded to be in a G1 cell cycle. Therefore, the invention provides a new therapeutic drug for clinical treatment of liver cancer, and the raw materials are natural medicinal materials, have wide sources and have good application prospects.

The invention discloses a preparation method of a cochlear organ chip integrated with a blood labyrinth barrier, and belongs to the field of biomedical engineering. The preparation method of the simulated blood labyrinth barrier comprises the following steps: constructing an endothelial cell culture cavity and a pericyte culture cavity, and separating the endothelial cell culture cavity and the pericyte culture cavity through a simulated basement membrane; and respectively inoculating percutaneous cells and endothelial cells into a percutaneous cell culture cavity and an endothelial cell culture cavity, and culturing to obtain the simulated blood lost barrier. The chip can effectively simulate the structure and the function of the BLB, and the barrier integrity of the BLB is evaluated through TEER (trans-epithelial electrical resistance) measurement and an apparent permeability coefficient. The invention also relates to application of the chip in NIHL drug screening, in particular to drug evaluation for oxidative stress induced inner ear organ injury. Through the platform, the protection effect of the candidate drugs on the TBHP-induced oxidative stress injury of the inner ear organs can be evaluated, and a new tool and thought are provided for developing novel NIHL treatment drugs.

The present invention relates to a damaged skin organoid model and a drug screening method using same, and is a technology that uses a technique for producing an air-liquid interface skin organoid, in which skin cells, appendages, nerve cells, adipocytes, and the like are formed as a structure similar to actual skin, and which produces damaged skin by irradiating the skin organoid with ultraviolet rays that simulate ultraviolet radiation reaching the earth's surface. In the present invention, by irradiation with simulated solar ultraviolet rays including 94.5% of UV-A and 5.5% of UV-B, the skin barrier was damaged and collagen degradation was promoted by increasing the activity of matrix metalloproteinases, and, at the same time, the characteristics of UV-damaged skin, such as increased secretion of pro-inflammatory cytokines, were successfully mimicked. Therefore, it is determined that the present invention will be effectively used as a UV-induced damage and photoaging model, and will serve as a useful technology for screening for potential therapeutic drugs.

The invention provides a new target for treating metabolism-related fatty liver diseases, a regulation molecule and application thereof. The invention discloses a novel target gene closely related to relieving or treating the metabolism-related fatty liver disease and a signal channel related to upstream and downstream regulation and control of the target gene for the first time. The invention discloses a new mechanism participated by the signal channel and used for regulating and controlling the metabolism-related fatty liver disease. Preferred remission / therapeutic agents are also disclosed.

A cage type support for bone grafting capable of achieving heat balance comprises a support shell and a base, and a multipurpose cavity is formed in the base. The inner cavity of the bracket shell is communicated with the multi-purpose chamber through a heat convection pipe group; the multipurpose cavity is configured to be a heat dissipation end communicated with the inner cavity, and heat balance of the inner cavity and the multipurpose cavity is achieved through a heat convection pipe set communicated between the multipurpose cavity and the inner cavity; a stable supporting foundation is provided, the osseointegration process is promoted, heat balance of the whole stent is achieved, the internal temperature of the femoral head is properly increased, local blood circulation of the femoral head is accelerated, cell activity is enhanced, metabolism is accelerated, proliferation and differentiation of related cells such as bone cells are promoted, angiogenesis and bone repair are promoted, and gas exchange is facilitated. The implant can be used for promoting the discharge of hydrops and pneumatosis, continuously releasing intraosseous pressure and providing a storage space and path for therapeutic drugs and / or nutritional ingredients, and the implant realizes multi-system collaboration and promotes overall rehabilitation.

The invention provides a novel therapeutic drug for treating Prom1 related retinal diseases. Specifically, the invention provides an optimized Prom1 gene expression cassette, an rAAV virus vector and a gene therapy drug. The medicine provided by the invention can specifically express the PROM1 protein in a retina photoreceptor layer, and is suitable for clinical application to treatment of Prom1 gene mutation related retinal diseases.

The invention provides a gene therapy drug for treating AMD (Amplified Maleic Disease). The invention provides an anti-VEGF fusion protein with a specific secretion signal peptide sequence. The anti-VEGF fusion protein can effectively express and secrete an anti-VEGF protein. The invention also provides a modified AAV vector for improving the retinal transduction efficiency of the anti-VEGF protein. The fusion protein and the modified AAV vector can be used for treating neovascular eye diseases.

A portable emergency response kit designed for rapid intervention in opioid overdose or cardiac arrest scenarios comprises a durable case with compartments for specific medical devices, such as opioid overdose treatment medication or an Automated External Defibrillator (AED). The case features a breakable closed circuit that is, upon opening, triggered to send a signal to notify emergency medical services (EMS) or predefined contacts of the kit's location.The system utilizes GPS module and may include dual-mode communication capabilities for reliable alert transmission in various environments. Additional features may include a transparent case material for visual confirmation of contents, tamper-evident seals, QR codes linked to instructional content, and a battery power source. The kit is designed to be user-friendly, incorporating ergonomic elements and optional accessories for enhanced portability and storage, ensuring rapid and effective response in critical situations.

The invention discloses a multi-stage leaching purification method of a targeted therapeutic drug. The multi-stage leaching purification method comprises the following steps: sequentially filling an adsorption column with a porous organic polymer layer and an adsorption ball layer; controlling the flow rate of the leacheate and the column temperature for leaching, and setting an adsorption saturation threshold value; carrier gas is adopted to heat and desorb the porous polymer layer, and carrier gas components are switched to heat and desorb the adsorption ball layer; the method comprises the following steps: introducing carrier gas carrying iodine vapor into an alkaline absorption tower to treat waste gas, eluting impurities of adsorption balls by adopting an acidic mixed solution, and performing catalytic degradation by combining ultraviolet light; a chelating agent solution is used for regenerating adsorption balls, a silver salt solution is used for heavily loading silver ions, an organic solvent is used for eluting and regenerating a porous polymer, regular calibration and part replacement are conducted on a system, and organic pollutants and radionuclides in a matrix are difficult to treat synchronously through a traditional single-layer adsorption material; according to the leaching purification method, the generation amount of radioactive waste liquid is remarkably reduced, and meanwhile the shielding protection requirement of the follow-up purification step is reduced.

Devices and methods for treating joint degeneration (e.g., intervertebral disc degeneration) are provided. An example method may comprise: (1) advancing a tip of an introducer needle into a nucleus pulpous of an intervertebral disc; (2) with the tip of the introducer needle in the nucleus pulpous, maneuvering, out of the tip of the introducer needle, a tip of a flexible needle into a region of a cartilaginous endplate (CEP) of the intervertebral disc; and (3) delivering, from an aperture of the flexible needle, therapeutic to the region of the CEP.

The invention discloses application of tangeretin in preparation of a medicine for treating hearing loss. The invention proposes and verifies that the tangeretin can effectively protect the spiral ganglion neurons for the first time, and avoids the death of the cells caused by cisplatin medication; experimental data show that the preventive tangeretin drug can effectively prevent hearing loss of adult mice and greatly relieve sensorineural deafness caused by cis-platinum, and a new thought is provided for clinical ototoxicity drug administration.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The invention discloses a construction method and application of a rabies virus RNA polymerase dual-luciferase report system, and belongs to the technical field of biology. In order to solve the technical problem that a report system for detecting the RABV RNA polymerase activity needs to be developed urgently, a Firefly luciferase fragment and a vector pcDNA3.1-SRV9-M-G obtained by amplifying M protein and G protein-deleted rabies virus SRV9 strain full-length plasmid are seamlessly connected, a recombinant luciferase report plasmid is constructed, the recombinant luciferase report plasmid and an auxiliary plasmid are combined, and the recombinant luciferase RNA polymerase activity detection system is constructed. And the RABV RNA polymerase dual-luciferase report system is formed by the Renilla luciferase report plasmid and the T7 promoter plasmid, and the RABV RNA polymerase dual-luciferase report system comprises the Renilla luciferase report plasmid and the T7 promoter plasmid. The system can accurately and efficiently detect the activity of RABV polymerase, and by virtue of the function, effective antiviral targets and therapeutic drugs can be screened out in an assisted manner.

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

The utility model discloses a cardiology department rehabilitation belt which comprises a belt body, a storage mechanism is arranged on the belt body, a heartbeat sensor is fixedly connected to the belt body, an elastic belt is arranged on the belt body, a son buckle is fixedly connected to the belt body, a shoulder belt is fixedly connected to the belt body, and buckling mechanisms are arranged at the two ends of the belt body. One end of the belt body is fixedly connected with an emergency button, the upper end of the belt body is provided with a charging port, the storage mechanism is designed, therapeutic drugs can be placed in the box body during daily treatment of a patient, the drugs are convenient to store, and if the storage mechanism is not needed, the storage mechanism can be taken down from the belt body through a hook-and-loop fastener, and the patient can conveniently take and place the drugs by himself / herself.

The invention discloses a back cumin treatment method which is used for relieving symptoms of patients with chronic obstructive pulmonary disease and chronic bronchitis. The method comprises the following steps: preparing a cumin ground medicine which comprises 9g of viola tianshanica, 9g of hollyhock seed, 9g of common fenugreek seed, 9g of dill seed, 9g of linseed, 9g of chamomile, 100g of sesame oil or olive oil and other materials, blending the medicine and oil or warm boiled water into a paste at 38-40 DEG C, applying the paste to lung positions (15 * 20cm, 0.3-0.5 cm in thickness) on two sides of the back of a patient, covering the lung positions with a preservative film, irradiating the lung positions with a TDP baking lamp which is not less than 20cm in height for 20-30 minutes, and cleaning the medicine applying positions after the process is finished. Viola tianshanica in the cumin geomedicine can clear away heat and toxic materials, diminish inflammation and relieve pain, hollyhock seeds can clear heat and induce diuresis, and relieve cough and asthma, through the treatment, the medicine efficiently permeates and quickly acts on diseased regions, the symptoms of patients are effectively relieved, and the life quality is improved.

The application discloses a kind of elastin-like polypeptide V 20 K 40 L, mRNA vaccine and preparation method and application in preparation tumor prevention, mitigation or treating drug.The elastin-like polypeptide carrier V 20 K 40 L provided by the application has good biocompatibility, and has no adverse reaction in vivo.The elastin-like polypeptide V 20 K 40 L provided by the application has amphiphilic structure, can be loaded Melan-A mRNA by hydrophobic self-assembly and electrostatic adsorption, and is in the state of shrinkage when higher than Tt temperature, which can prevent the uncontrollable leakage of mRNA.Furthermore, V 20 K 40 L contains lysosome escape peptide, which can further improve the transfection efficiency of mRNA by promoting lysosome escape.The elastin-like polypeptide V 20 K 40 L in the application can deliver Melan-A mRNA efficiently and safely, and realize the prevention and treatment of melanoma.

Provided is a nanoparticle-mediated targeted drug delivery robotic system for the precision treatment of breast cancer. **Solution**: This system 100 integrates robot-assisted movement, real-time image processing, an artificial intelligence-driven control mechanism, and sensor-guided targeting to ensure the accurate delivery of therapeutic drugs to cancer tissue while minimizing damage to surrounding healthy structures. The system consists of a six-degree-of-freedom articulated robotic arm 102, a drug release control actuator 114, a targeting module 106 equipped with optical and electromagnetic sensors, and a control unit 110 equipped with machine learning technology for real-time decision-making. The image subsystem 112 utilizes magnetic resonance imaging, ultrasound, and infrared imaging to provide a detailed anatomical and functional view of breast tissue. The artificial intelligence-driven technology of this system continuously processes image and sensor data, guides the robotic arm towards the tumor site, and dynamically adjusts the positioning based on physiological movements and tissue changes. A force feedback mechanism minimizes tissue damage during insertion, and an automatic calibration system finely adjusts the movement of the robotic arm in real time. The actuator is designed as an electric syringe or a controlled valve system to accurately administer nanoparticle-based therapeutic drugs directly to the tumor, optimizing the drug efficacy while suppressing systemic toxicity.

The application discloses the use of carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone in the prevention and treatment of candida infection, belonging to the technical field of candida infection prevention and treatment. Carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone is used as the only active ingredient for preparing a medicine for preventing or treating diseases caused by candida infection, wherein the candida is candida albicans and / or candida auris; or it is used for preparing a bacteriostatic and / or bactericidal product of candida, wherein the candida is candida albicans and / or candida auris. FCCP shows good inhibition of strain growth, good inhibition of biofilm effect and good mitochondria breaking effect in the antibacterial experiments of various candida (wild type candida albicans, drug resistant candida albicans and drug resistant candida auris). Thus, a new treatment drug for candida albicans and candida auris infection is provided.

The invention provides a traditional Chinese medicine formula and application thereof in preparation of a medicine for treating cough, and belongs to the technical field of traditional Chinese medicines. According to the traditional Chinese medicine formula provided by the invention, 4-6 parts of white ginseng, 2-4 parts of American ginseng, 4-6 parts of schisandra chinensis, 2-4 parts of momordica grosvenori and 2-4 parts of rhizoma zingiberis are compatible with one another to jointly achieve the effects of tonifying qi and yin, warming lung to dissipate fluid retention, clearing heat and moistening lung and astringing lung to arrest cough, the cough caused by various disease causes is comprehensively treated, and the characteristics of treatment based on syndrome differentiation and holism of traditional Chinese medicine are reflected; the traditional Chinese medicine composition has a remarkable curative effect on traditional Chinese medicine clinical cough, can effectively relieve cough symptoms, change traditional Chinese medicine syndromes and improve lung functions, is good in safety, provides a new traditional Chinese medicine treatment scheme for cough treatment, and has a certain clinical application value.

The present invention relates to an artificial nucleic acid molecule, a related product thereof and use thereof in the preparation of a medicament for DNA or RNA-based therapy, and to the use of a 3 '-untranslated region element (i.e., 3'-UTR) in said artificial nucleic acid molecule for translating a coding region of a nucleic acid molecule into a polypeptide or protein encoded by said coding region, and a method of obtaining RNA, polypeptide or protein. According to the present invention, the specific 3 '-UTR element capable of improving the RNA translation performance is included, such that the artificial nucleic acid molecule has the high RNA translation performance so as to provide the high potential value and the high application prospect in the development of the RNA treatment drug.